Neurocrine Biosciences, Inc. (NBIX) Balance Sheet

The balance sheet is clearly strengthening, driven by robust retained earnings accumulation, which turned positive in 2025Q2 and reached $724M by 2026Q2. This growth is supported by strong operational performance, with revenue accelerating and margins expanding, as noted in prior income statement analysis. The increase in assets is partly due to a $2.4B acquisition in 2026Q2, which added goodwill and intangibles, but the equity base has grown organically as well, suggesting a healthy trajectory.

Total debt has fluctuated between $251M and $908M over the past ten quarters, with a spike in 2025Q3 to $908M, likely related to acquisition financing, but it was subsequently reduced to $402M by 2026Q2. The D/E ratio remains low at 0.10, well below peer averages, suggesting that leverage is strategic rather than necessity-driven. This low leverage provides financial flexibility and reduces refinancing risk, though the recent acquisition may have introduced integration risks that could impact cash flow durability.

The asset mix is evolving from a relatively asset-light model with modest PPE to one with significant intangibles, as evidenced by the $500.6M goodwill addition in 2026Q2. This raises the risk of future impairment if the acquired business underperforms, which investors should monitor. PPE has been gradually declining, reflecting minimal capital intensity typical of biotech, but the new intangibles may not generate the same tangible collateral value, potentially affecting borrowing capacity.

The equity base has grown from $2.4B to $4.0B, driven primarily by retained earnings, which turned positive in 2025Q2 and have since accumulated rapidly. This indicates that the company is generating sustainable profits and reinvesting them, rather than relying on external financing or dilution. However, stock-based compensation averaging $54M per quarter, as noted in prior analysis, could dilute shareholders over time, though it remains moderate relative to revenue.

Despite a decline in the current ratio from a peak of 4.37 in 2024Q3 to 1.87 in 2026Q2, the company maintains a solid liquidity buffer, with cash and short-term investments covering current liabilities. The cash position has been volatile, ranging from $139.7M to $713.0M, reflecting acquisition and buyback activities. Given the robust operating cash flow, as highlighted in prior cash flow analysis, the liquidity position appears sufficient to cover near-term obligations and fund ongoing operations.